

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://www.fdi-lab.com) on Apr 5, 2025

CHO

RRID:CVCL_0213

Type: Cell Line

Proper Citation

(ICLC Cat# ATL95003, RRID:CVCL_0213)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0213

Proper Citation: (ICLC Cat# ATL95003, RRID:CVCL_0213)

Sex: Female

Defining Citation: [PMID:4120885](https://pubmed.ncbi.nlm.nih.gov/4120885/), [PMID:13598821](https://pubmed.ncbi.nlm.nih.gov/13598821/), [PMID:34050613](https://pubmed.ncbi.nlm.nih.gov/34050613/)

Category: Spontaneously immortalized cell line

Name: CHO

Synonyms: Chinese Hamster Ovary, CHO-ori

Cross References: BTO:BTO_0000246, CLO:CLO_0002421, EFO:EFO_0022760, MCCL:MCC:0000102, CLDB:cl721, CLDB:cl722, CLDB:cl724, CCRID:1101HAM-PUMC000116, CCRID:5301HAM-KCB83004YJ, ChEMBL-Cells:ChEMBL3308072, ChEMBL-Targets:ChEMBL613853, CLS:603479, ECACC:85050302, IBRC:C10028, ICLC:ATL95003, KCB:KCB 82012YJ, KCB:KCB 83004YJ, Lonza:755, MeSH:D016466, NCBI_Iran:C111, PubChem_Cell_line:CVCL_0213, Wikidata:Q56646

ID: CVCL_0213

Vendor: ICLC

Catalog Number: ATL95003

Record Creation Time: 20250131T194724+0000

Record Last Update: 20250131T195252+0000

Ratings and Alerts

No rating or validation information has been found for CHO.

No alerts have been found for CHO.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 719 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Bosch R, et al. (2024) Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model. *British journal of pharmacology*, 181(12), 1874.

Mineva ND, et al. (2024) A Novel Class of Human ADAM8 Inhibitory Antibodies for Treatment of Triple-Negative Breast Cancer. *Pharmaceutics*, 16(4).

Frey G, et al. (2024) A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy. *mAbs*, 16(1), 2322562.

Moquist PN, et al. (2024) Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation. *Bioconjugate chemistry*, 35(6), 855.

Srinivas K, et al. (2024) Differential Cytotoxic Effects of Cell-Free Supernatants of Emerging Pathogens *Escherichia albertii* and *Escherichia fergusonii* on Four Cell Lines Reveal Vero Cells as a Putative Candidate for Cytotoxicity Analysis. *Microorganisms*, 12(11).

Chuinsiri N, et al. (2024) Calcium-sensing receptor regulates Kv7 channels via Gi/o protein signalling and modulates excitability of human induced pluripotent stem cell-derived nociceptive-like neurons. *British journal of pharmacology*, 181(15), 2676.

Lin Y, et al. (2024) Microenvironment-induced CREPT expression by cancer-derived small extracellular vesicles primes field cancerization. *Theranostics*, 14(2), 662.

Kutzsche J, et al. (2024) An orally available Cav2.2 calcium channel inhibitor for the treatment of neuropathic pain. *British journal of pharmacology*, 181(12), 1734.

Schoellerman J, et al. (2024) Characterization of tritiated JNJ-GluN2B-5 (3-[³H] 1-(azetidin-1-yl)-2-(6-(4-fluoro-3-methyl-phenyl)pyrrolo[3,2-b]pyridin-1-yl)ethanone), a high affinity GluN2B radioligand with selectivity over sigma receptors. *Journal of neurochemistry*, 168(9), 2654.

Mihlan M, et al. (2024) Neutrophil trapping and necrocytosis, mast cell-mediated processes for inflammatory signal relay. *Cell*, 187(19), 5316.

Xu B, et al. (2024) Characterization of a novel variant in KCNJ16, encoding Kir5.1 channel. *Physiological reports*, 12(20), e70083.

Trøstheim M, et al. (2023) Opioid antagonism in humans: a primer on optimal dose and timing for central mu-opioid receptor blockade. *Neuropsychopharmacology* : official publication of the American College of Neuropsychopharmacology, 48(2), 299.

Delaunois A, et al. (2023) Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti-seizure medication: Levetiracetam case study. *Pharmacology research & perspectives*, 11(1), e01059.

Ghanbarpour A, et al. (2023) Structure-free antibody paratope similarity prediction for in silico epitope binning via protein language models. *iScience*, 26(2), 106036.

Das N, et al. (2023) Tryptase ? regulation of joint lubrication and inflammation via proteoglycan-4 in osteoarthritis. *Nature communications*, 14(1), 1910.

Cadang L, et al. (2023) A Highly Efficient Workflow for Detecting and Identifying Sequence Variants in Therapeutic Proteins with a High Resolution LC-MS/MS Method. *Molecules (Basel, Switzerland)*, 28(8).

Schuler SMM, et al. (2023) Full Profiling of GE81112A, an Underexplored Tetrapeptide Antibiotic with Activity against Gram-Negative Pathogens. *Microbiology spectrum*, 11(3), e0224722.

Li P, et al. (2023) Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels. *Frontiers in pharmacology*, 14, 1177003.

Englert H, et al. (2023) Targeting NETs using dual-active DNase1 variants. *Frontiers in immunology*, 14, 1181761.

Svilenov HL, et al. (2023) Extrinsic stabilization of antiviral ACE2-Fc fusion proteins targeting SARS-CoV-2. *Communications biology*, 6(1), 386.